BioSpace News Archive

Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held March 15-18, 2021. Oral Platform Presentation: Thursday, March 18, 5:30 – 5:45 p.m. ET

Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK), (NASDAQ: CHEKZ), today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) application,

Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced the finalization of arrangements for the completion of the investigational new drug (“IND”) package for the company’s lead drug candidate and its submission to the United States Food and Drug Administration (“FDA”).

Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID) Targeting safinamide label extension for PD LID in key global markets

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31 st Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT).

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting a business and pipeline update at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference and will participate on the psychedelics panel as follows:

Strongbridge Biopharma plc (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that management will present at Oppenheimer’s 31 st Annual Healthcare Conference on Wednesday, March 17, at 10:00 a.m. ET.

EyeYon Medical announced today the completion of a $25 million in a Series C funding, led by a global strategic leader in the ophthalmic industry and CR-CP Life Science Fund.

Fresenius Kabi announced today the immediate availability in the United States of Foscarnet Sodium Injection. Fresenius Kabi Foscarnet Sodium Injection is available in 6000 mg / 250 mL bottle.

ResMed, a world-leading digital health company, announced the results of a nationwide survey of 1,000 adults, which revealed that for half of Americans, stress over the past year is negatively impacting the quality of their sleep – and many are ignoring sleep challenges that could point to a larger underlying health concern.